Complete Story
 

OPA COVID-19 Vaccines and Therapeutics: September 20, 2022 Update

 

New Funds Available from ODH Uninsured COVID-19 Vaccine Grant

The Ohio Department of Health (ODH) still has a small amount of funds available to reimburse pharmacies for vaccinating patients who are uninsured with the COVID-19 vaccine. Vaccinators are encouraged to apply as soon as possible. Applicants shall not seek reimbursement through any other source for vaccines administered with this funding. Click here to download the Application for Uninsured Vaccine Administration Reimbursement. Downloaded applications will need to be signed, then emailed to Procurement@odh.ohio.gov.

Funding will be awarded on a first-come, first-served basis. Vaccine providers will receive the money upfront based on the provider’s estimated number of vaccinations of uninsured individuals from the date of award through June 30, 2023. Providers will have the option of payment by electronic fund transfer or by check. Providers will be required as part of the agreement to submit quarterly reports with a total number of vaccinations of uninsured individuals to be reviewed and validated by ODH. Providers will be required to return any funding received in excess of the actual vaccines administered. Please submit any questions regarding this funding opportunity to ODH by email at Procurement@odh.ohio.gov.

Reminder: ODH Ordering Guidance for COVID-19 Bivalent Booster Formulations 
The Ohio Department of Health (ODH) shared that Ohio vaccine providers who preordered the bivalent vaccines can begin administering vaccinations as soon as shipments arrive and providers have had a chance to review storage, handling, and administration details found on the EUA fact sheets. Providers who placed preorders are urged to check their email messages for delivery updates from vaccine distributors. Shipment information also is available through the Vaccine Ordering Management System (VOMS). 

How to order bivalent COVID-19 vaccine boosters:
ODH is accepting orders for the bivalent boosters through VOMS. 

Reminder: FDA Provides Additional Guidance for Paxlovid Therapy Evaluation 
The FDA provided an updated Patient Eligibility Screening Checklist to help prescribers evaluate potential drug interactions for Paxlovid therapy for COVID-19. Dispensing and prescribing providers should review each patient’s full list of medications and use other resources to evaluate for potential drug interactions in patients who take medications that are not included on the Fact Sheet or checklist at this time. A listing of additional resources is provided at the end of the checklist.


OPA is working diligently to facilitate communication between state decision-makers and member pharmacists. OPA has created multiple COVID-19 resources, including a COVID-19 Vaccine Information WebpageCOVID-19 Testing Hub, and COVID-19 Resources Webpage, on the OPA website www.ohiopharmacists.org under the Resources drop-down box. Please contact Myriam Shaw Ojeda, Director of Pharmacy Extension and Public Health Initiatives, for further questions at mshawojeda@ohiopharmacists.org.

Printer-Friendly Version